Search

The investigational oral drug MDV3100 significantly improved overall survival in patients with advanced prostate cancer, results of a large, phase III study show.

… Tuesday, January 31, 2012 The investigational oral drug MDV3100 significantly improved overall survival in patients with advanced prostate cancer , results of a large, phase III study show. The findings were presented today at the 2012 American Society of Clinical Oncology (ASCO) Genitourinary Cancers

Last week, Governor Kathy Hochul signed the New York State Budget for FY 2023 that includes a key provision which will allow more New Yorkers from underserved communities access to care at Memorial Sloan Kettering Cancer Center (MSK) and other NCI-designated cancer centers in the state.

… Monday, April 18, 2022 Last week, Governor Kathy Hochul signed the New York State Budget for FY 2023 that includes a key provision which will allow more New Yorkers from underserved communities access to care at Memorial Sloan Kettering Cancer Center (MSK) and other NCI-designated cancer centers in the

La semana pasada, la gobernadora Kathy Hochul firmó el presupuesto del estado de Nueva York para el año fiscal 2023, que incluye una disposición clave que permitirá que más neoyorquinos de comunidades marginadas accedan a la atención en Memorial Sloan Kettering Cancer Center (MSK) y otros centros oncológicos designados por el Instituto Nacional del Cáncer (NCI) en el estado.

… Monday, April 18, 2022 La semana pasada, la gobernadora Kathy Hochul firmó el presupuesto del estado de Nueva York para el año fiscal 2023, que incluye una disposición clave que permitirá que más neoyorquinos de comunidades marginadas accedan a la atención en Memorial Sloan Kettering Cancer Center (MSK

In this interview, hematologic oncologist Eytan Stein, Director of the Program for Drug Development in Leukemia, talks about the latest advances in treatment for AML and how people can benefit from receiving their treatment at MSK.

… Monday, November 18, 2024 Acute myeloid leukemia (AML) is one of the most common types of blood cancer. The word “acute” means that the cancer can advance quickly and needs to be treated right away. The word “myeloid” refers to the type of blood cells that are cancerous. Myeloid cells are blood cells

Eight scientists are poised to receive their doctorates and embark on careers tackling problems in human disease through biomedical research. Their years of dedication and training will be recognized on May 18, 2022, when they will be awarded their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK). This year’s commencement marks the school’s 11th graduating class since admitting its first students in 2006.

… Monday, May 16, 2022 Eight scientists are poised to receive their doctorates and embark on careers tackling problems in human disease through biomedical research. Their years of dedication and training will be recognized on May 18, 2022, when they will be awarded their PhD degrees from the Gerstner Sloan

… Tuesday, September 3, 2024 Dear MSK Community, Our knowledge of cancer — what it is and how it progresses — has developed at a staggering pace over the past 20 years. Today, thanks to remarkable advances in the understanding of how cancer cells behave and evolve, many led by MSK, researchers have devised

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments:

… Wednesday, April 27, 2022 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Jorge S. Reis-Filho Named a Susan G. Komen Scholar Jorge S. Reis-Filho Jorge S. Reis-Filho, MD, PhD, FRCPath, Chief, Experimental Pathology Service, was named a Susan G. Komen Scholar

Patients of European ancestry are more likely to find a match to the latest targeted cancer drugs than patients of other ancestries, according to new MSK research. This trend could exacerbate disparities in cancer outcomes.

… Thursday, January 9, 2025 Nearly half of all new cancer drugs approved by the U.S. Food and Drug Administration (FDA) over the past quarter-century have received that approval based on their ability to target genetic changes driving tumor growth. Medical oncologists use information about the genetic

Researchers from Memorial Sloan Kettering Cancer Center recently discovered that the most frequently used cancer cell lines in ovarian cancer research are not suitable models of ovarian cancer.

… Friday, July 12, 2013 Researchers from Memorial Sloan Kettering Cancer Center recently discovered that the most frequently used cancer cell lines in ovarian cancer research are not suitable models of ovarian cancer. Their findings are the result of a detailed review of genomic data that recently became

The MSK team’s goal was to get at the underlying defects in cells that these mutations cause.

… Monday, July 1, 2019 Summary MSK researchers have made new discoveries about how changes in a family of cancer-causing genes can lead to epigenetic changes. A family of genes called IDH are associated with cancer. These genes make enzymes called isocitrate dehydrogenases. The enzymes help break down